BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Depletion of Neuroguidin/CANu1 sensitizes human osteosarcoma U2OS cells to doxorubicin

  • Received : 2010.10.13
  • Accepted : 2010.12.01
  • Published : 2011.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Osteosarcoma is a primary bone cancer which occurs mainly in children. Neuroguidin/CANu1 is a nucleolar protein involved in the maintenance of ribosomal structure. In this study, we investigated the effect of Neuroguidin/CANu1 depletion on the response of osteosarcoma cells to doxorubicin. In normal circumstances, Neuroguidin/CANu1 is localized at nucleoli, which translocates to nuclear foci in the presence of doxorubicin. shRNA knockdown of Neuroguidin/CANu1 did not affect cell viability in the absence of doxorubicin, but led to enhanced cytotoxicity in doxorubicin-treated cells. Doxorubicin increased the population of apoptotic cells by 3-fold in Neuroguidin/CANu1-depleted cells compared to that in control cells. Depletion of Neuroguidin/CANu1 mRNA induced the expression of p21 and the cleavage of PARP, leading to increased caspase-3/7 activity. Together, these results suggest that Neuroguidin/CANu1 is required for maintaining cellular homeostasis and may contribute to the improved efficiency of chemotherapy.

Keywords

References

  1. Daw, N. C., Billups, C. A., Rodriguez-Galinodo, C.,McCarville M. B., Rao, B. N., Cain, A. M., Jenkins, J. J.,Neel, M. D. and Meyer W. H. (2006) Metastaticosteosarcoma. Cancer 106, 403-412. https://doi.org/10.1002/cncr.21626
  2. Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G.U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M.,Werner, M., Winkelmann, W., Zoubek, A., Jurgens, H.and Winkler, K. (2002) Prognostic factors in high-gradeosteosarcoma of the extremities or trunk: an analysis of1,702 patients treated on neoadjuvant cooperative osteosarcomastudy group protocols. J. Clin. Oncol. 20, 776-790. https://doi.org/10.1200/JCO.20.3.776
  3. Niswander, L. M. and Kim, S. Y. (2010) Stratifying osteosarcoma:minimizing and maximizing therapy. Curr.Oncol. Rep. 12, 266-270. https://doi.org/10.1007/s11912-010-0106-3
  4. Orosco, A., Fromigue, O., Bazille, C., Entz-Werle, N.,Levillain, P., Marie, P. J. and Modrowski, D. (2007)Syndecan-2 affects the basal and chemotherapy-inducedapoptosis in osteosarcoma. Cancer Res. 67, 3708-3715. https://doi.org/10.1158/0008-5472.CAN-06-4164
  5. Sihn, C. R., Lee, Y. S., Jeong, J. S., Park, K. and Kim, S. H.(2008) CANu1, a novel nucleolar protein, accumulatedon centromere in response to DNA damage. Genes Cells13, 787-796. https://doi.org/10.1111/j.1365-2443.2008.01205.x
  6. Jung, M. Y., Lorenz, L. and Richter, J. D. (2006) Translationalcontrol by neuroguidin, a eukaryotic initiation factor 4E and CPEB binding protein. Mol. Cell Biol. 26,4277-4287. https://doi.org/10.1128/MCB.02470-05
  7. Tembe, V. and Henderson, B. R. (2007) Protein traffickingin response to DNA damage. Cell Signal 19, 1113-1120. https://doi.org/10.1016/j.cellsig.2007.03.001
  8. Mo, Y. Y., Yu, Y., Shen, Z. and Beck, W. T. (2002)Nucleolar delocalization of human topoisomerase I in responseto topotecan correlates with sumoylation of theprotein. J. Biol. Chem. 277, 2958-2964. https://doi.org/10.1074/jbc.M108263200
  9. Daniely, Y., Dimitrova, D. D. and Borowiec, J. A. (2002)Stress-dependent nucleolin mobilization mediated byp53-nucleolin complex formation. Mol. Cell Biol. 22,6014-6022. https://doi.org/10.1128/MCB.22.16.6014-6022.2002
  10. Blander, G., Zalle, N., Daniely, Y., Taplick, J., Gray, M.D. and Oren, M. (2002) DNA damage-induced translocationof the Werner helicase is regulated by acetylation.J. Biol. Chem. 277, 50934-50940. https://doi.org/10.1074/jbc.M210479200
  11. Condemine, W., Takahashi, Y. and Le, B. M. (2007) A nucleolartargeting signal in PML-I addresses PML to nucleolarcaps in stressed or senescent cells. J. Cell Sci. 120,3219-3227. https://doi.org/10.1242/jcs.007492
  12. Kurki, S., Latonen, L. and Laiho, M. (2003) Cellular stressand DNA damage invoke temporally distinct Mdm2, p53and PML complexes and damage-specific nuclear relocalization.J. Cell Sci. 116, 3917-3925. https://doi.org/10.1242/jcs.00714
  13. Alastalo, T. P., Hellesuo, M., Sandqvist, A., Hietakangas,V., Kallio, M. and Sistonen, L. (2003) Formation of nuclearstress granules involves HSF2 and coincides with thenucleolar localization of Hsp70. J. Cell Sci. 116, 3557-3570. https://doi.org/10.1242/jcs.00671
  14. Yuan, X. W., Zhu, X. F., Huang, X. F., Sheng, P. Y., He, A.S., Yang, Z. B., Deng, R., Feng, G. K. and Liao, W. M.(2007) Interferon-alpha enhances sensitivity of human osteosarcomaU2OS cells to doxorubicin by p53-dependentapoptosis. Acta Pharmacol. Sin. 28, 1835-1841. https://doi.org/10.1111/j.1745-7254.2007.00662.x
  15. Bruland, O. S. and Pihl, A. (1997) On the current managementof osteosarcoma. A critical evaluation and a proposalfor a modified treatment strategy. Eur. J. Cancer 33,1725-1731. https://doi.org/10.1016/S0959-8049(97)00252-9
  16. Lambert, L. A., Qiao, N., Hunt, K. K., Lambert, D. H.,Mills, G. B., Meijer, L. and Keyomarsi, K. (2008) Autophagy:a novel mechanism of synergistic cytotoxicity betweendoxorubicin and roscovitine in a sarcoma model.Cancer Res. 68, 7966-7974. https://doi.org/10.1158/0008-5472.CAN-08-1333
  17. Zucchi, R. and Danesi, R. (2003) Cardiac toxicity of antineoplasticanthracyclines. Curr. Med. Chem. AnticancerAgents 3, 151-171. https://doi.org/10.2174/1568011033353434
  18. Schimmel, K. J., Richel, D. J., van den Brink, R. B. andGuchelaar, H. J. (2004) Cardiotoxicity of cytotoxic drugs.Cancer Treat. Rev. 30, 181-191. https://doi.org/10.1016/j.ctrv.2003.07.003
  19. Liu, S., Bishop, W. R. and Liu, M. (2003) Differential effectsof cell cycle regulatory protein p21(WAF1/Cip1) onapoptosis and sensitivity to cancer chemotherapy. DrugResist. Updat. 6, 183-195. https://doi.org/10.1016/S1368-7646(03)00044-X
  20. Agrawal, S., Agarwal, M. L., Chatterjee-Kishore, M., Stark,G. R. and Chisolm, G. M. (2002) Stat1-dependent, p53-independentexpression of p21(waf1) modulates oxysterolinducedapoptosis. Mol. Cell Biol. 22, 1981-1992. https://doi.org/10.1128/MCB.22.7.1981-1992.2002
  21. Teraishi, F., Kadowaki, Y., Tango, Y., Kawashima, T.,Umeoka, T., Kagawa, S., Tanaka, N. and Fujiwara, T.(2003) Ectopic p21sdi1 gene transfer induces retinoic acidreceptor beta expression and sensitizes human cancercells to retinoid treatment. Int. J. Cancer 103, 833-839. https://doi.org/10.1002/ijc.10892
  22. Lincet, H., Poulain, L., Remy, J. S., Deslandes, E., Duigou,F., Gauduchon, P. and Staedel, C. (2000) The p21 (cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxiceffect of cisplatin in human ovarian carcinomacells. Cancer Lett. 161, 17-26. https://doi.org/10.1016/S0304-3835(00)00586-3
  23. Qin, L. F. and Ng, I. O. (2001) Exogenous expression ofp21(WAF1/CIP1) exerts cell growth inhibition and enhancessensitivity to cisplatin in hepatoma cells. Cancer Lett.172, 7-15. https://doi.org/10.1016/S0304-3835(01)00701-7
  24. Klibanov, S. A., O'Hagan, H. M. and Ljungman, M.(2001) Accumulation of soluble and nucleolar-associatedp53 proteins following cellular stress. J. Cell Sci. 114,1867-1873.
  25. Zhang, S., Hemmerich, P. and Grosse, F. (2004) Nucleolarlocalization of the human telomeric repeat binding factor2 (TRF2). J. Cell Sci. 117, 3935-3945. https://doi.org/10.1242/jcs.01249
  26. Mayer, C. and Grummt, I. (2005) Cellular stress and nucleolarfunction. Cell Cycle 4, 1036-1038. https://doi.org/10.4161/cc.4.8.1925
  27. Montanaro, L., Trere, D. and Derenzini, M. (2008)Nucleolus, ribosomes, and cancer. Am. J. Pathol. 173,301-310. https://doi.org/10.2353/ajpath.2008.070752
  28. Derenzini, M., Montanaro, L. and Trere, D. (2008) Whatthe nucleolus says to a tumour pathologist. Histopathology54, 753-762. https://doi.org/10.1111/j.1365-2559.2008.03168.x
  29. Meng, L., Lin, T. and Tsai, R. Y. (2008) Nucleoplasmicmobilization of nucleostemin stabilizes MDM2 and promotesG2-M progression and cell survival. J. Cell Sci. 121,4037-4046. https://doi.org/10.1242/jcs.037952
  30. Ma, H. and Pederson, T. (2008) Nucleophosmin is a bindingpartner of nucleostemin in human osteosarcoma cells.Mol. Biol. Cell 19, 2870-2875. https://doi.org/10.1091/mbc.E08-02-0128
  31. Jafarnejad, S. M., Mowla, S. J. and Matin, M. M. (2008)Knocking-down the expression of nucleostemin significantlydecreases rate of proliferation of rat bone marrowstromal stem cells in an apparently p53-independentmanner. Cell Prolif. 41, 28-35. https://doi.org/10.1111/j.1365-2184.2007.00505.x
  32. Dai, M. S., Sun, X. X. and Lu, H. (2008) Aberrant expressionof nucleostemin activates p53 and induces cellcycle arrest via inhibition of MDM2. Mol. Cell Biol. 28,4365-4376. https://doi.org/10.1128/MCB.01662-07
  33. Woo, L. L., Futami, K., Shimamoto, A., Furuichi, Y. andFrank, K. M. (2006) The Rothmund-Thomson gene productRECQL4 localizes to the nucleolus in response to oxidativestress. Exp. Cell Res. 312, 3443-3457. https://doi.org/10.1016/j.yexcr.2006.07.023
  34. Otake, Y., Soundararajan, S., Sengupta, T. K., Kio, E. A.,Smith, J. C., Pineda-Roman, M., Stuart, R. K., Spicer, E. K.and Fernandes, D. J. (2007) Overexpression of nucleolinin chronic lymphocytic leukemia cells induces stabilizationof bcl2 mRNA. Blood 109, 3069-3075.
  35. Kaelin, Jr. W. G. (2005) The concept of synthetic lethalityin the context of anticancer therapy. Nat. Rev. Cancer 5,689-698. https://doi.org/10.1038/nrc1691
  36. Chan, D. A. and Giaccia, A. J. (2008) Targeting cancercells by synthetic lethality: autophagy and VHL in cancertherapeutics. Cell Cycle 7, 2987-2990. https://doi.org/10.4161/cc.7.19.6776
  37. Bommi-Reddy, A. and Kaelin, Jr. W. G. (2010) SlayingRAS with a synthetic lethal weapon. Cell Res. 20, 119-121. https://doi.org/10.1038/cr.2010.16
  38. Kaelin, Jr. W. G. (2009) Synthetic lethality: a frameworkfor the development of wiser cancer therapeutics. GenomeMed. 1, 99. https://doi.org/10.1186/gm99
  39. Wang, Y. A., Johnson, S. K., Brown, B. L. and Dobson, P.R. (2009) Differential enhancement of the anti-cancer effectof doxorubicin by Akt inhibitors on human breastcancer cells with differing genetic backgrounds. Oncol.Rep. 21, 437-442.

Cited by

  1. The Complexity of Human Ribosome Biogenesis Revealed by Systematic Nucleolar Screening of Pre-rRNA Processing Factors vol.51, pp.4, 2013, https://doi.org/10.1016/j.molcel.2013.08.011
  2. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth bothin vivoandin vitro vol.6, pp.4, 2012, https://doi.org/10.1016/j.molonc.2012.04.002